Notice on Convening the 2nd Extraordinary General Meeting in 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Notice on Convening the 2nd Extraordinary General Meeting in 2026
Filed with SSE · · 6 pages · Chinese
Release
Mabwell (Shanghai) Bioscience Co., Ltd. on 6ix
Earlier from Mabwell (Shanghai) Bioscience
- 2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
- Report for Q1 2026
- Announcement on the Public Offering Price of Overseas Listed Foreign Shares (H-shares)
- Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
- 2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
Later from Mabwell (Shanghai) Bioscience
- World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application
- Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection)
- Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
- Announcement on Engagement of H-share Audit Institution for 2026
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
Follow Mabwell (Shanghai) Bioscience into a list and get an email when it puts out news.
Follow Mabwell (Shanghai) Bioscience